{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:06:57Z","timestamp":1770563217509,"version":"3.49.0"},"reference-count":61,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            The aim of this study was to describe treatment patterns among patients with acromegaly who are newly treated with acromegaly medical therapy.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Data from IQVIA Pharmetrics Plus\n            <jats:sup>\u00ae<\/jats:sup>\n            Database from 1\u00a0January 2013 to 30\u00a0June 2023 were used to identify patients with acromegaly who started a new acromegaly medical therapy and observe their treatment patterns. Patients were required to have at least 12\u00a0months of data without any acromegaly therapy (medication or surgery) prior to the index date and at least 6\u00a0months of follow-up. Comorbidities were measured during the baseline period. Adherence, persistence, medication and switching were measured during follow-up.\n            <jats:bold>Results:<\/jats:bold>\n            A total of 453 patients with acromegaly who were newly treated with acromegaly medical therapy and had no evidence of acromegaly therapy for at least 12\u00a0months were identified. Among these patients, 46.1% (n\u00a0=\u00a0206) were treated with cabergoline as their index treatment, 24.5% (n\u00a0=\u00a0111) with injectable octreotide, 15.0% (n\u00a0=\u00a068) with lanreotide, 5.5% (n\u00a0=\u00a025) with bromocriptine, 4.9% (n\u00a0=\u00a022) with pegvisomant, 2.2% (n\u00a0=\u00a010) with pasireotide, 1.1% (n\u00a0=\u00a05) with oral octreotide, 0.4% (n\u00a0=\u00a02) with cabergoline\u00a0+\u00a0octreotide, and 0.2% (n\u00a0=\u00a01) with cabergoline\u00a0+\u00a0lanreotide. By the end of the follow-up period, 54.3% (n\u00a0=\u00a0246) were not on any treatment, 19.6% (n\u00a0=\u00a089) remained on the index treatment, and the remaining 26.0% (n\u00a0=\u00a0118) switched to another treatment.\n            <jats:bold>Conclusion:<\/jats:bold>\n            This study contributed to the growing evidence that patients with acromegaly are not well-served by current therapeutic options, as indicated by high rates of treatment discontinuation, switching\u00a0and add-on therapy. However, treatment switching and add-on therapy represent ongoing efforts to optimize patient care toward more effective and tolerable treatments. Expanded treatment options may serve an unmet need in this patient population.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0080","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T10:38:57Z","timestamp":1751971137000},"source":"Crossref","is-referenced-by-count":1,"title":["Adherence, duration\u00a0and healthcare costs in a real-world population of patients with acromegaly"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-4285","authenticated-orcid":false,"given":"Tiffany P","family":"Quock","sequence":"first","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-6153","authenticated-orcid":false,"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-9463","authenticated-orcid":false,"given":"Ashis K","family":"Das","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-1384","authenticated-orcid":false,"given":"Amanda","family":"Speller","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-5113","authenticated-orcid":false,"given":"Marian H","family":"Tarbox","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3567-0862","authenticated-orcid":false,"given":"Stacy K","family":"Rattana","sequence":"additional","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3591-7293","authenticated-orcid":false,"given":"Ingrid E","family":"Paulson","sequence":"additional","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":false,"given":"Michael S","family":"Broder","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_7_3_2","volume-title":"StatPearls","author":"Adigun OO","year":"2024","unstructured":"Adigun OO, Nguyen M, Fox TJ, Anastasopoulou C. Acromegaly. In: StatPearls. StatPearls Publishing, FL, USA (2024). Available from: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK431086\/"},{"issue":"11","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu M","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10(11), 804\u2013826 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"e_1_3_7_5_2","volume-title":"StatPearls","author":"Bello MO","year":"2024","unstructured":"Bello MO, Garla VV. Gigantism and Acromegaly. In: StatPearls. StatPearls Publishing, FL, USA (2024). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538261\/"},{"issue":"2","key":"e_1_3_7_6_2","first-page":"499","article-title":"Acromegaly: current therapies benefits and burdens","volume":"15","author":"Yedinak C","year":"2018","unstructured":"Yedinak C, Pulaski-Liebert KJ, Adelman DT, Williams J. Acromegaly: current therapies benefits and burdens. Clin. Pract. 15(2), 499\u2013511 (2018).","journal-title":"Clin. Pract."},{"issue":"9","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed S","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S84887","article-title":"The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences","volume":"9","author":"Plunkett C","year":"2015","unstructured":"Plunkett C, Barkan AL. The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer. Adher. 9, 1093\u20131099 (2015).","journal-title":"Patient Prefer. Adher."},{"issue":"3","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40801-015-0039-0","article-title":"Treatment patterns and economic burden in patients treated for acromegaly in the USA","volume":"2","author":"Chuang CC","year":"2015","unstructured":"Chuang CC, Bhurke S, Chen SY, Dinet J, Brulais S, Gabriel S. Treatment patterns and economic burden in patients treated for acromegaly in the USA. Drugs \u2013 Real World Outcomes 2(3), 299\u2013309 (2015).","journal-title":"Drugs \u2013 Real World Outcomes"},{"issue":"10","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"bvad104","DOI":"10.1210\/jendso\/bvad104","article-title":"Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis","volume":"7","author":"Fleseriu M","year":"2023","unstructured":"Fleseriu M, Barkan A, Brue T Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis. J. Endocr. Soc. 7(10), bvad104 (2023).","journal-title":"J. Endocr. Soc."},{"issue":"3","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"A64","DOI":"10.1016\/j.jval.2015.03.375","article-title":"Barriers to treatment adherence associated with acromegaly in the United States: provider's perspective","volume":"18","author":"Liu S","year":"2015","unstructured":"Liu S, Xu Y, Begelman SM, Shi L. Barriers to treatment adherence associated with acromegaly in the United States: provider's perspective. Value Health 18(3), A64 (2015).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/03007995.2024.2314244","article-title":"Preferences for different treatment options among people living with acromegaly in the US","volume":"40","author":"Sisco J","year":"2024","unstructured":"Sisco J, Furumalm M, Yssing C, Okkels A, Zavisic S. Preferences for different treatment options among people living with acromegaly in the US. Curr. Med. Res. Opin. 40(4), 657\u2013664 (2024).","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"e_1_3_7_13_2","first-page":"29","article-title":"Canadian consensus guidelines for the diagnosis and management of acromegaly","volume":"29","author":"Ezzat S","year":"2006","unstructured":"Ezzat S, Serri O, Chik CL Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin. Invest. Med. 29(1), 29\u201339 (2006).","journal-title":"Clin. Invest. Med."},{"issue":"5","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael JD","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J. Clin. Endocrinol. Metab. 99(5), 1825\u20131833 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao A","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3), 235\u2013247 (2016).","journal-title":"Pituitary"},{"issue":"16","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant","volume":"342","author":"Trainer PJ","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171\u20131177 (2000).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina A","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667\u2013678 (2020).","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina A","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1), 7\u201322 (2024).","journal-title":"Pituitary"},{"issue":"7","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina A","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannav\u00f2 S High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 102(7), 2454\u20132464 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina A","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161(2), 331\u2013338 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina A","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243\u2013248 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","article-title":"Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time","volume":"105","author":"Ghajar A","year":"2019","unstructured":"Ghajar A, Jones PS, Guarda FJ Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J. Clin. Endocrinol. Metab. 105(3), e532\u2013e543 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11102-022-01219-x","article-title":"Endocrine disorders after primary gamma knife radiosurgery for pituitary adenomas: a systematic review and meta-analysis","volume":"25","author":"Palmisciano P","year":"2022","unstructured":"Palmisciano P, Ogasawara C, Ogasawara M Endocrine disorders after primary gamma knife radiosurgery for pituitary adenomas: a systematic review and meta-analysis. Pituitary 25(3), 404\u2013419 (2022).","journal-title":"Pituitary"},{"issue":"4","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11102-012-0457-x","article-title":"Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications","volume":"16","author":"Wilson TJ","year":"2013","unstructured":"Wilson TJ, McKean EL, Barkan AL, Chandler WF, Sullivan SE. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary 16(4), 459\u2013464 (2013).","journal-title":"Pituitary"},{"key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2152-7806.175896","article-title":"Effect of repeated transsphenoidal surgery in recurrent or residual pituitary adenomas: a systematic review and meta-analysis","volume":"7","author":"Heringer LC","year":"2016","unstructured":"Heringer LC, de Oliveira MF, Rotta JM, Botelho RV. Effect of repeated transsphenoidal surgery in recurrent or residual pituitary adenomas: a systematic review and meta-analysis. Surg. Neurol. Int. 7, 14 (2016).","journal-title":"Surg. Neurol. Int."},{"key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/PPA.S119570","article-title":"Communication practices and awareness of resources for acromegaly patients among endocrinologists","volume":"10","author":"Polanco-Briceno S","year":"2016","unstructured":"Polanco-Briceno S, Glass D, Plunkett C. Communication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer. Adher. 10, 2531\u20132541 (2016).","journal-title":"Patient Prefer. Adher."},{"key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"693409","DOI":"10.3389\/fpubh.2021.693409","article-title":"Do we need a specific guideline for assessment and improvement of acromegaly patients adherence?","volume":"9","author":"Kamusheva M","year":"2021","unstructured":"Kamusheva M, Parvanova A, Rusenova Y, Vandeva S, Elenkova A. Do we need a specific guideline for assessment and improvement of acromegaly patients adherence? Front. Public Health 9, 693409 (2021).","journal-title":"Front. Public Health"},{"issue":"4","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11102-014-0608-3","article-title":"Discontinuation of somatostatin analogs while acromegaly is in long-term remission","volume":"18","author":"Hatipoglu E","year":"2015","unstructured":"Hatipoglu E, Bozcan S, Kadioglu P. Discontinuation of somatostatin analogs while acromegaly is in long-term remission. Pituitary 18(4), 554\u2013560 (2015).","journal-title":"Pituitary"},{"issue":"6","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito D","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur. J. Endocrinol. 182(6), 523\u2013531 (2020).","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2004-2009","article-title":"Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly","volume":"90","author":"Puder JJ","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J. Clin. Endocrinol. Metab. 90(4), 1972\u20131978 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40618-024-02519-8","article-title":"Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly","volume":"48","author":"Gasco V","year":"2024","unstructured":"Gasco V, Prencipe N, Cuboni D Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly. J. Endocrinol. Invest. 48(4), 919\u2013929 (2024).","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/pharmaceutics15020438","article-title":"Adherence to acromegaly treatment and analysis of the related factors\u2014a real-world study in Bulgaria","volume":"15","author":"Kamusheva M","year":"2023","unstructured":"Kamusheva M, Vandeva S, Mitov K Adherence to acromegaly treatment and analysis of the related factors\u2014a real-world study in Bulgaria. Pharmaceutics 15(2), 438 (2023).","journal-title":"Pharmaceutics"},{"issue":"4","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11102-024-01400-4","article-title":"Exploring potential influencing factors of inadherence to specialist aftercare and long-term medication in patients with acromegaly","volume":"27","author":"Siegel S","year":"2024","unstructured":"Siegel S, Giese S, Honegger J Exploring potential influencing factors of inadherence to specialist aftercare and long-term medication in patients with acromegaly. Pituitary 27(4), 403\u2013415 (2024).","journal-title":"Pituitary"},{"key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu M","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front. Endocrinol. 12, 627711 (2021).","journal-title":"Front. Endocrinol."},{"issue":"3","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger CJ","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, St\u00f6rmann S Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur. J. Endocrinol. 174(3), 355\u2013362 (2016).","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer EB","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr. Disord. 20(1), 117 (2020).","journal-title":"BMC Endocr. Disord."},{"issue":"5","key":"e_1_3_7_37_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova J","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin. Neuropharmacol. 34(5), 179\u2013181 (2011).","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"e_1_3_7_38_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11102-012-0432-6","article-title":"Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases","volume":"16","author":"Burton T","year":"2013","unstructured":"Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 16(3), 354\u2013362 (2013).","journal-title":"Pituitary"},{"issue":"5","key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1185\/03007995.2015.1125870","article-title":"Patterns of pharmacologic treatment in US patients with acromegaly","volume":"32","author":"Broder MS","year":"2016","unstructured":"Broder MS, Chang E, Ludlam WH, Neary MP, Carmichael JD. Patterns of pharmacologic treatment in US patients with acromegaly. Curr. Med. Res. Opin. 32(5), 799\u2013805 (2016).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_7_40_2","unstructured":"IQVIA. IQVIA PharMetrics\u00ae Plus Fact Sheet (2025). Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/fact-sheets\/iqvia-pharmetrics-plus-fs.pdf"},{"issue":"2","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"e220320","DOI":"10.1001\/jamanetworkopen.2022.0320","article-title":"Trends in disenrollment and reenrollment within US Commercial Health Insurance Plans, 2006\u20132018","volume":"5","author":"Fang H","year":"2022","unstructured":"Fang H, Frean M, Sylwestrzak G, Ukert B. Trends in disenrollment and reenrollment within US Commercial Health Insurance Plans, 2006\u20132018. JAMA Netw. Open 5(2), e220320 (2022).","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11102-016-0725-2","article-title":"Challenges in the diagnosis and management of acromegaly: a focus on comorbidities","volume":"19","author":"Abreu A","year":"2016","unstructured":"Abreu A, Tovar AP, Castellanos R Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4), 448\u2013457 (2016).","journal-title":"Pituitary"},{"issue":"4","key":"e_1_3_7_43_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","article-title":"Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines","volume":"26","author":"Slagboom TNA","year":"2023","unstructured":"Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML. Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary 26(4), 319\u2013332 (2023).","journal-title":"Pituitary"},{"issue":"1","key":"e_1_3_7_44_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/clinem\/dgz050","article-title":"The course of obstructive sleep apnea syndrome in patients with acromegaly during treatment","volume":"105","author":"Wolters TLC","year":"2020","unstructured":"Wolters TLC, Roerink SHPP, Drenthen LCA The course of obstructive sleep apnea syndrome in patients with acromegaly during treatment. J. Clin. Endocrinol. Metab. 105(1), 290\u2013304 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"642131","DOI":"10.3389\/fendo.2021.642131","article-title":"Complications and comorbidities of acromegaly\u2014retrospective study in Polish center","volume":"12","author":"Rolla M","year":"2021","unstructured":"Rolla M, Jawiarczyk-Przyby\u0142owska A, Halupczok-\u017by\u0142a J Complications and comorbidities of acromegaly\u2014retrospective study in Polish center. Front. Endocrinol. 12, 642131 (2021).","journal-title":"Front. Endocrinol."},{"key":"e_1_3_7_46_2","unstructured":"US Bureau of Labor Statistics Division of Consumer Prices and Price Indexes. Consumer Price Index (2021). Available from: https:\/\/www.bls.gov\/cpi\/"},{"issue":"4","key":"e_1_3_7_47_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","article-title":"Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases","volume":"17","author":"Broder MS","year":"2014","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17(4), 333\u2013341 (2014).","journal-title":"Pituitary"},{"issue":"9","key":"e_1_3_7_48_2","first-page":"e28722","article-title":"A comprehensive review of four clinical practice guidelines of acromegaly","volume":"14","author":"Ogedegbe OJ","year":"2022","unstructured":"Ogedegbe OJ, Cheema AY, Khan MA A comprehensive review of four clinical practice guidelines of acromegaly. Cureus 14(9), e28722 (2022).","journal-title":"Cureus"},{"key":"e_1_3_7_49_2","unstructured":"Melmed S Katznelson L. Treatment of acromegaly. UpToDate (2023). Available from: https:\/\/www.uptodate.com\/contents\/treatment-of-acromegaly"},{"issue":"24","key":"e_1_3_7_50_2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJM198106113042402","article-title":"No effect of bromocriptine in acromegaly","volume":"304","author":"Lindholm J","year":"1981","unstructured":"Lindholm J, Riishede J, Vestergaard S, Hummer L, Faber O, Hagen C. No effect of bromocriptine in acromegaly. N. Engl. J. Med. 304(24), 1450\u20131454 (1981).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_51_2","volume-title":"Patterns of pharmacotherapy changes and switches suggest unmet need in US patients with acromegaly","author":"Carmichael JD","year":"2015","unstructured":"Carmichael JD, Neary MP, Chang E, Broder MS, Cherepanov D, Ludlam WH. Patterns of pharmacotherapy changes and switches suggest unmet need in US patients with acromegaly. 2015 Annual SNO Meeting, TX, USA (2015)."},{"issue":"9","key":"e_1_3_7_52_2","doi-asserted-by":"crossref","first-page":"bvac114","DOI":"10.1210\/jendso\/bvac114","article-title":"Preoperative medical treatment for patients with acromegaly: yes or no?","volume":"6","author":"Albarel F","year":"2022","unstructured":"Albarel F, Cuny T, Graillon T, Dufour H, Brue T, Castinetti F. Preoperative medical treatment for patients with acromegaly: yes or no? J. Endocr. Soc. 6(9), bvac114 (2022).","journal-title":"J. Endocr. Soc."},{"issue":"1","key":"e_1_3_7_53_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cen.14790","article-title":"Preoperative medical treatments and surgical approaches for acromegaly: a systematic review","volume":"98","author":"Papaioannou C","year":"2023","unstructured":"Papaioannou C, Druce M. Preoperative medical treatments and surgical approaches for acromegaly: a systematic review. Clin. Endocrinol. (Oxf). 98(1), 14\u201331 (2023).","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"6","key":"e_1_3_7_54_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11102-024-01404-0","article-title":"Acromegaly and COVID-19, lessons, and new opportunities","volume":"27","author":"Varlamov EV","year":"2024","unstructured":"Varlamov EV, Fleseriu M. Acromegaly and COVID-19, lessons, and new opportunities. Pituitary 27(6), 935\u2013944 (2024).","journal-title":"Pituitary"},{"issue":"2","key":"e_1_3_7_55_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-020-02565-1","article-title":"Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era","volume":"71","author":"Giustina A","year":"2021","unstructured":"Giustina A, Legg E, Cesana BM, Frara S, Mortini P, Fleseriu M. Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. Endocrine 71(2), 273\u2013280 (2021).","journal-title":"Endocrine"},{"issue":"3","key":"e_1_3_7_56_2","first-page":"278","article-title":"Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature","volume":"66","author":"Kizilgul M","year":"2022","unstructured":"Kizilgul M, Duger H, Nasiroglu NI Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature. Arch. Endocrinol. Metab. 66(3), 278\u2013285 (2022).","journal-title":"Arch. Endocrinol. Metab."},{"issue":"5","key":"e_1_3_7_57_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret L","year":"2011","unstructured":"Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96(5), 1327\u20131335 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"e_1_3_7_58_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","article-title":"Cabergoline treatment in acromegaly: pros","volume":"46","author":"Marazuela M","year":"2014","unstructured":"Marazuela M, Ramos-Lev\u00ed A, Sampedro-N\u00fa\u00f1ez M, Bernabeu I. Cabergoline treatment in acromegaly: pros. Endocrine 46(2), 215\u2013219 (2014).","journal-title":"Endocrine"},{"issue":"1","key":"e_1_3_7_59_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000218323","article-title":"Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide","volume":"90","author":"Jallad RS","year":"2009","unstructured":"Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1), 82\u201392 (2009).","journal-title":"Neuroendocrinology"},{"issue":"4","key":"e_1_3_7_60_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu M","year":"2021","unstructured":"Fleseriu M, F\u00fchrer-Sakel D, van der Lely AJ More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur. J. Endocrinol. 185(4), 525\u2013538 (2021).","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"e_1_3_7_61_2","doi-asserted-by":"crossref","first-page":"101910","DOI":"10.1016\/j.beem.2024.101910","article-title":"Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess","volume":"38","author":"MacFarlane J","year":"2024","unstructured":"MacFarlane J, Korbonits M. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess. Best Pract. Res. Clin. Endocrinol. Metab. 38(4), 101910 (2024).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"11","key":"e_1_3_7_62_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4158\/EP161397.OR","article-title":"Incidence and prevalence of acromegaly in the United States: a claims-based analysis","volume":"22","author":"Broder MS","year":"2016","unstructured":"Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH. Incidence and prevalence of acromegaly in the United States: a claims-based analysis. Endocr. Pract. 22(11), 1327\u20131335 (2016).","journal-title":"Endocr. Pract."},{"issue":"3","key":"e_1_3_7_63_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton T","year":"2016","unstructured":"Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary 19(3), 262\u2013267 (2016).","journal-title":"Pituitary"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:53:12Z","timestamp":1756457592000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2025-0080"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0080","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e250080"}}